# A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers

> **NCT05789342** · PHASE1 · COMPLETED · sponsor: **Jiangxi Qingfeng Pharmaceutical Co. Ltd.** · enrollment: 54 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** GP681
- **DRUG:** Rosuvastatin
- **DRUG:** Digoxin
- **DRUG:** Itraconazole
- **DRUG:** Oseltamivir

## Key facts

- **NCT ID:** NCT05789342
- **Lead sponsor:** Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-15
- **Primary completion:** 2023-09-11
- **Final completion:** 2023-10-31
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05789342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05789342, "A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05789342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*